Genmab A/S (GE9.F)
212.50
0.50 (0.24%)
At close: Jan 14, 2025, 5:16 PM
undefined% (undefined)
| Bid | n/a |
| Market Cap | 13.50B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 4.859 |
| PE Ratio (ttm) | 43.73 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 19 |
| Avg. Volume (20D) | 70 |
| Open | 215.00 |
| Previous Close | 212.00 |
| Day's Range | 212.50 - 215.00 |
| 52-Week Range | 188.00 - 289.10 |
| Beta | undefined |
About GE9.F
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosi...
Industry n/a
Sector n/a
IPO Date Oct 23, 2000
Employees 2,635
Stock Exchange XETRA
Ticker Symbol GE9.F
Website https://www.genmab.com